Dr. Jasmine C. Hollinger, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 731 S Pear Orchard Rd Ste 16, Ridgeland, MS 39157 Phone: 601-672-2044 |
Amanda Daggett, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 113 W Jackson St Ste 2c, Ridgeland, MS 39157 Phone: 601-607-8222 Fax: 601-914-4804 |
Dr. Sethelle Lucas Flowers, MD Dermatology Medicare: May Accept Medicare Assignments Practice Location: 299 Highway 51, Suite F1, Ridgeland, MS 39157 Phone: 601-853-2440 Fax: 601-853-2460 |
Dr. Gary Glenn Bolton, M. D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 305 Highland Park Cv, Ridgeland, MS 39157 Phone: 601-206-9433 Fax: 601-206-5428 |
News Archive
Stimulation of a receptor in the brain that controls insulin responses has been shown to halt or diminish the neurodegeneration of Alzheimer's disease, providing evidence that the disease can be treated in its early stages, according to a study by researchers at Rhode Island Hospital and Brown Medical School.
A research team from the University of Copenhagen and University of Helsinki demonstrates it is possible to predict individual preferences based on how a person's brain responses match up to others. This could potentially be used to provide individually-tailored media content - and perhaps even to enlighten us about ourselves.
On the heels of a White House defense of President Barack Obama's decision to skip the XIX International AIDS Conference in Washington D.C. (Agence France-Presse: "US defends Obama no-show at AIDS Conference," By Kerry Sheridan, July 18, 2012) AIDS Healthcare Foundation (AHF) released a TV ad featuring Archbishop Desmond Tutu of South Africa warning of the consequences of a "global abandonment of AIDS."
Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa's RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
New Leaf Venture Partners (NLV Partners) announced today the closing of the second tranche of a $26 million investment in Oxford Immunotec Ltd., a leading manufacturer and marketer of T cell-based diagnostic tests. The Series D financing was led by NLV Partners, and additional participants included new investor Kaiser Permanente Ventures and existing investors Clarus Ventures, Wellington Partners, Kuwait-based National Technology Enterprises Company, SPARK Ventures, DFJ Esprit, Oxford University and The Dow Chemical Company.
› Verified 2 days ago